Fixed Dose Rate Gemcitabine and Cisplatin Followed by Chemoradiation for Locally Advanced Pancreatic Cancer

Phase Ⅱ Trial of Fixed Dose Rate Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiation With Capecitabine in Patients With Locally Advanced Pancreatic Cancer

This is a phase Ⅱ trial of fixed dose rate gemcitabine and cisplatin chemotherapy followed by chemoradiation with capecitabine in patients with locally advanced pancreatic cancer.

The main purpose of this study is to evaluate the efficacy and safety of fixed dose rate gemcitabine and cisplatin chemotherapy followed by chemoradiation with capecitabine in patients with locally advanced pancreatic cancer.

Inclusion Criteria:

• unresectable locally advanced pancreatic cancer

• no distant metastasis

• histologically confirmed adenocarcinoma of pancreas

• 18-75 of age

• ECOG performance status 0-2

• normal marrow function :

  • WBC at least 3,000/mm3 OR Absolute neutrophil count at least 1,500/mm3
  • Platelet count at least 100,000/mm3

• normal liver function :

  --Bilirubin no greater than 2.0 mg/dL AST less than 3 times upper limit of normal (ULN)

• normal renal function :

  --Creatinine no greater than 1.5 times ULN

• signed informed consent